Determining the best dose of CYAD-02 for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, phase I, multi-center study aims to find the recommended dose of CYAD-02 in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants will undergo non-myeloablative preconditioning chemotherapy before receiving CYAD-02 infusions. The study will evaluate three dose levels of CYAD-02 using a staggered enrollment approach based on a Fibonacci 3+3 design. Non-progressive patients may receive additional infusions without prior preconditioning. The overall study duration is expected to last approximately 15 years.

Why it matters

Who can join: the full rules

Inclusion Criteria (main):

* The patient must not be eligible for standard of care therapy and have one of the following hematological malignancy:

  1. A confirmed relapsed or refractory acute AML (i.e. ≥ 5% blasts in bone marrow or in peripheral blood) with revised European LeukemiaNet (ELN) 2017 risk stratification for favorable, intermediate or adverse groups, after at least one prior therapy defined as either

     * Recurrence of disease after a first complete remission and not eligible for a second course of induction therapy, or
     * Recurrence of disease after a second complete remission, or
     * Failure to achieve a Complete Response after induction chemotherapy.
  2. A confirmed MDS as defined by revised International Prognostic Scoring System criteria for intermediate, high-risk or very high-risk disease or MDS with Tumor Protein 53 mutation as detected by next-generation sequencing, after failure of prior treatment with at least 4 cycles of azacitidine or decitabine defined as:

     * No response to treatment,
     * Loss of response at any time point, or
     * Intolerance to therapy.
* The patient must have evaluable disease as defined by:

  * Revised Recommendations of the International Working Group (IWG) for Diagnosis, Standardization of Response Criteria for AML patients,
  * IWG 2006 Uniform Response Criteria for patients with MDS.
* The absolute peripheral blast count should be \< 15,000/L.
* The patient must have adequate hepatic and renal functions, as assessed by standard laboratory criteria.
* The patient must have a left ventricular ejection fraction of ≥ 40 %, as determined by echocardiography or a multigated acquisition scan.
* The patient must have a Forced Expiratory Volume (FEV) in the first second /Forced Vital Capacity = 0.7 with FEV-1 at 50 % predicted (GOLD 1 or 2 severity) as determined by spirometry

Exclusion Criteria (main):

* Patients with a confirmed or history of tumor involvement in the central nervous system
* Patients who have received any cancer therapy with therapeutic intent (investigational agent or not)
* Patients with any positive serology test results at baseline
* Patients who plan to receive, are concurrently receiving or have received any investigational agent within 3 weeks before the planned day for the first CYAD-02 infusion
* Patients with uncontrolled intercurrent illness or serious uncontrolled medical disorder
* Patients with significant coagulation disorder or who are receiving treatment with warfarin derivatives, heparin or direct oral anticoagulants
* Patients who have active infections
* Patients with documented history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease

Where it's running

• University of Kansas Cancer Center
  Fairway, Kansas, United States Recruiting
• Uz Leuven
  Leuven, Belgium Recruiting
• Chu Liege
  Liège, Belgium Recruiting
• Az Delta
  Roeselare, Belgium Recruiting
• Mayo Clinic Cancer Center
  Jacksonville, Florida, United States Not yet recruiting

Study contacts

• Study coordinator: Frederic LEHMANN, MD, PhD
• Email: flehmann@celyad.com
• Phone: 003210394100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Adding FHD-286 to low‑dose decitabine and venetoclax for adverse‑risk AML

  This trial tests whether adding FHD-286 to a low‑dose decitabine plus venetoclax regimen helps people with newly diagnosed adverse‑risk acute myeloid leukemia or AML that progressed after one prior therapy.

  Recruiting Phase 1 Montefiore Medical Center · The Bronx, New York · NCT07283094

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Induction and consolidation using fludarabine, cytarabine, idarubicin, and venetoclax for acute myeloid leukemia

  This trial tests whether adding venetoclax to induction and consolidation chemotherapy (fludarabine, cytarabine, and idarubicin) helps adults 18–65 with newly diagnosed acute myeloid leukemia or high-blast myelodysplastic syndrome achieve deeper remissions than standard cytarabine/daunorubicin therapy.

  Recruiting Phase 2 OHSU Knight Cancer Institute · Portland, Oregon · NCT07228273

• RPT1G for adults with relapsed or refractory acute myeloid leukemia and high-risk MDS

  This study will test whether the drug RPT1G is safe and find the best dose for adults whose AML or high-risk MDS has come back or not responded to treatment.

  Recruiting at 2 sites Phase 1 Remedy Plan, Inc. · New York, New York and 1 other locations · NCT07107126

• FLAG‑Ida chemotherapy followed by reduced‑intensity total‑body irradiation and donor stem cell transplant for adults 60+ with adverse‑risk AML or other high‑grade myeloid cancers

  This trial tests whether FLAG‑Ida chemotherapy given immediately before lower‑intensity total‑body radiation and a donor stem cell transplant can improve outcomes for adults 60 and older with newly diagnosed adverse‑risk acute myeloid leukemia or similar high‑grade myeloid cancers.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07046078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.